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Abstract
deoxynucleoside triphosphate (dNTPs) are the reduced nucleotides used as the building blocks and energy source for deoxy-
ribonucleic acid (DNA) replication and maintenance in all living systems. They are present in highly regulated amounts and
ratios in the cell, and their balance has been implicated in the most important cell processes, from determining the fidelity
of DNA replication to affecting cell fate. Furthermore, many cancer drugs target biosynthetic enzymes in dNTP metabolism,
and mutations in genes directly or indirectly affecting these pathways that are the cause of devastating diseases. The accu-
rate and systematic measurement of these pools is key to understanding the mechanisms behind these diseases and their
treatment. We present a new method for measuring dNTP pools from biological samples, utilizing the current state-of-the-
art polymerase method, modified to a solid-phase setting and optimized for larger scale measurements.
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Introduction
Deoxyribonucleic acid (DNA) carries the genetic information of
all known living organisms, and its synthesis utilizes deoxynu-
cleoside triphosphates (dNTPs), both as building blocks and as
energy source for the polymerization reaction. dNTP pools de-
pend on cell cycle and cell and tissue type, with proliferating
cells typically having higher pools than post-mitotic cells [1].
dNTPs are typically present at very low concentrations, which
are tightly regulated via the expression, regulation and localiza-
tion of their biosynthetic and catabolic enzymes [2–4]. These
enzymes form a complex, highly regulated network in animal
cells, involving the nuclear, mitochondrial and cytoplasmic
compartments. These interlinked pathways include the
biosynthetic de novo pathway and the parallel cytoplasmic and
mitochondrial salvage pathways [5, 6].
The absolute amounts and ratios of the different dNTPs in
time and space have been shown to be critical for a wide range
of cellular processes, including DNA replication fidelity and mu-
tagenesis [7, 8], DNA repair, cell cycle progression and regula-
tion, mitochondrial DNA (mtDNA) maintenance function and
oncogenic and apoptotic processes [9]. Because of the muta-
genic effects of imbalanced dNTP pools, they have been studied
in detail in the context of cancer biology. However, accumulat-
ing data points to tight co-regulation of the mitochondrial and
cytoplasmic pools, evidenced by defects in the core synthetic
enzymes causing depletion or mutagenesis of mtDNA [10, 11].
These disorders present varying tissue specificity and different
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ages of onset, typically with multi-systemic devastating conse-
quences [12–14]. Furthermore, disorders of mitochondrial DNA
maintenance can secondarily affect the cytoplasmic dNTP pool
balance [15, 16], underscoring the intimate crosstalk of the dif-
ferent compartmentalized dNTP pools. Preclinical evidence sug-
gest that some mtDNA instability disorders could be treated
with nucleosides [17–19]. However, knowledge of the regulation
of the dNTP pools in pathological metabolic states or upon sup-
plementation therapies is still scarce, and sensitive methodol-
ogy is needed.
The most widely used approach to measure dNTP concen-
trations from biological samples is based on a polymerase as-
say using radioactively labelled substrate, first proposed in
the late 1960s [20] and further applied and developed two dec-
ades later [21]. This traditional method is laborious and multi-
step, challenging its sensitivity. After different modifications
and the replacement of the Klenow fragment for a thermosta-
ble polymerase to improve ribonucleotide discrimination [22],
the most recent update for this method was developed for the
measurement of mitochondrial dNTP pools [23]. The assay
relies on the specificity of a polymerase to utilize the dNTPs
present in the sample, and bind them on a designed template,
together with a different radiolabelled dNTP which will be in-
corporated proportionally. The amount of the radioactive la-
belled products (newly synthesized oligonucleotides) together
with a standard series of known dNTP concentrations, pro-
vides a quantitative result. However, the field has been ham-
pered by the recently restricted commercial availability of
specific materials needed for this protocol, motivating method
development.
We present here the adaptation of the dNTP measurement
into a solid-phase format, utilizing combined knowledge from
the conventional polymerase-based dNTP measurement and
the ‘solid-phase mini-sequencing’ principle of single-nucleotide
detection [24, 25]. This allows a microtitre-plate-based, auto-
matable approach, with an accurate measurement of a large
number of samples, improving efficiency, safety and accuracy
of the methodology.
Materials and methods
Figure 1A shows an example of the reaction in the setting of the
present method, being used to measure deoxycytidine triphos-
phate (dCTP).
Biotinylated oligonucleotides and primer
Table 1 below shows the sequences of the primer and the oligo-
nucleotides used in the reaction. The templates are labelled
‘Oligo’þN, with N indicating the base of the specific dNTP to be
measured with that template and the primer being common to
all reactions.
The biotin-labelled oligonucleotides should be High-perfor-
mance liquid chromatography (HPLC)-purified, and the primer
diluted to 5 lM concentration for the reaction, aliquoted and
stored at 20C.
Reagents and equipment
The content in parenthesis indicates the name of the product/
company used in the set-up
• 60% methanol in water, kept at 20C.
• 50 mM NaOH (made fresh every 4 weeks).
• Thermostable DNA polymerase (DyNAzyme II DNA Polymerase
by ThermoFisher Scientific), with its 10x optimized Enzyme
Buffer, stored at 20C.
• 0.5 M dithiothreitol (DTT) in small aliquots stored at 20C (sin-
gle use because of instability).
• dNTP mix stock, 40 mM dNTPs (10 mM each) (Bioline), and series
dilutions until 1 mM stored at 20C.
• [8-3H(N)]-Deoxyadenosine 50-triphosphate Tetrasodium Salt in
1:1 ethanol:water mixture (PerkinElmer), stored at 20C.
• [Methyl-3H]-Deoxythymidine 50-Triphosphate Tetrasodium Salt
in 1:1 ethanol:water mixture (PerkinElmer), stored at 20C.
• Phosphate buffered Saline (PBS).
• TWEENVR 20 (Amresco).
Figure 1: (A) Schematic description of the reaction principle using dCTP measurement as an example. (A1) Affinity capture of biotinylated oligonucleotide OligoC to
streptavidin-coated plate. (A2) Polymerization: priming of the template, followed by the proportional incorporation of the measured nucleotide (dCTP) and the radiola-
belled nucleotide (dATP*). (A3) Alkaline release of the labelled chain and radioactive count. (B) Example of standard curves and slopes to be used in the data analysis,
with the regression’s calculated R2 for each nucleotide measurement. (C) Equation for the analysis of the CPM obtained from the procedure, utilizing the resulting slope
from the standards and the blank, as well as the recorded dilution factors and cell number to obtain the concentration of the nucleotide per million cells.
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• TENT solution (40 mM Tris-HCl, 1 mM EDTA, 50 mM NaCl, 0.1%
TWEENVR 20, pH 8.0–8.8).
• Biotinylated oligonucleotides and primer (Sigma Aldrich), stock
and dilutions in 20C.
• Streptavidin-coated 96-well plate (BioBind Streptavidin Strip
Assembled Solid by Thermo Scientific).
• Ultima GoldTM liquid scintillation cocktail for aqueous and non-
aqueous samples (PerkinElmer).
• Scintillation vials and beta counter (MicroBeta2 by PerkinElmer).
• Microplate washer (WellwashTM by Thermo Labsystems).
• Speed vacuum concentrator.
• Countess automated cell counter (Invitrogen).
dNTP isolation
1. Culture cells in Petri dishes to an ideal minimum of 1 x 106
cells. As dNTPs vary greatly between dividing and non-
dividing cells and throughout the cell cycle, plan to harvest
the cells in similar confluency and cell cycle stage. Wash the
cells carefully with cold PBS and detach by trypsinization.
2. For normalization, count the cell concentration in the sus-
pension. Then pellet the cells in a microcentrifuge at 250g,
and store the pellet at 80C.
3. For the isolation, add 1.5 ml of cold (20C) 60% methanol in
water and vortex thoroughly. Then incubate for at least 1 h
at 80C.
4. Pellet the insoluble cell contents for 15 min at maximum
speed (20 000g at 4C); incubate the samples at 95C for
3 min, cool down on ice and pellet again similarly.
5. Collect the supernatant and transfer it to a new tube.
Desiccate the supernatant with a speed vacuum concentra-
tor until fully dry.
6. Store the solid extract at 80C until analysis.
Solid-phase radioactive polymerase reaction
1. Affinity capture of oligonucleotides:
Each dNTP will be measured in a separate well. Mark the
plates carefully for the four dNTP reaction, for the standard
series and sample replicates. Each measurement replicate
requires four wells (one per dNTP), and it is recommended
to have at least duplicates at different dilutions to confirm
linearity. The standard series of six concentrations will use
24 wells.
Transfer 2.5 ll of the specific template oligonucleotide into
each streptavidin-coated well, and add 47.5 ll of a 0.1%
TWEENVR in PBS solution. Incubate the plate at 37C for 1.5
h with gentle shaking (Table 2).
2. Discard the liquid from the wells, and wash the wells thor-
oughly four times at room temperature with 200 ml of TENT
solution. An automated plate washer can be used. Tap the
wells dry against tissue papers after the washes.
3. Standards:
Prepare a standard dilution series of a commercial dNTP
mixture, with the following concentrations: 80 nM, 40 nM,
20 nM, 10 nM, 5 nM, and a water blank.
4. Sample preparation:
Dissolve the frozen solid nucleotide extract in cold sterile
water (normally 100 ml, modify according to the cell num-
ber), vortex thoroughly and keep on ice for 10 min.
5. Prepare replicates of the different dilution coefficients (nor-
mally 1:5 and 1:10) for each sample to be measured, in a
volume sufficient for four reactions per dilution (minimum
50 ml).
6. Reaction:
Prepare master-mixes for each nucleotide to be mea-
sured according to Table 3. [3H]-dATP is used for measur-
ing dTTP, dCTP and dGTP (the wells with OligoT, OligoC
and OligoG) in the sample, while [3H]-dTTP is used for
the dATP (OligoA) reaction mixture. Since the radiola-
belled dNTPs are stored in ethanol:water mixture, the
molar concentration of each batch should be calculated
from the activity per volume and specific radioactivity
(usually 1mCi/ml and 10–25 Ci/mmol), and the solvent of
the required amount evaporated with a speed-vacuum
concentrator and dissolved in water, as recommended
by [23]. A 1:3 dilution of the radiolabel with cold dATP or
dTTP is also described by [23] to lower the specific radio-
activity and thus the costs without appreciable loss of
sensitivity.
7. Incubate the plate at 55C for 1 h, with a flotation device in
a water bath.
8. Discard the contents of the wells and perform the washing
process as in step 2.
Table 1: Detail of the primers and biotinylated oligonucleotides used for the reactions. The initial after ’Oligo’ indicates the base of the dNTP to
be measured
Sequence (50-30) Length
Primer CCTGTCTCATACACAGACAC 20 bp
OligoA [B]AAATAAATAAATAAATAAATGGACAGAGTATGTGTCTGTG 40 bp
OligoT [B]TTATTATTATTATTATTAGGACAGAGTATGTGTCTGTG 38 bp
OligoC [B]TTTGTTTGTTTGTTTGTTTGGGACAGAGTATGTGTCTGTG 40 bp
OligoG [B]TTTCTTTCTTTCTTTCTTTCGGACAGAGTATGTGTCTGTG 40 bp
Table 2: Composition of the affinity capture reaction mixture
Volume (ll) Final concentration
PBS/TWEENVR solution 47.5
5 lM oligonucleotide 2.5 0.25 lM
Total volume 50.0
Table 3: Composition of the polymerase reaction mixture
Volume (ll) Final concentration
10x polymerase buffer 5 1x
0.5 M DTT 0.5 5 mM
15 lM radiolabelled dNTP 2.5 0.75 lM
5 lM primer 2.5 0.25 lM
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9. Release the newly synthesized labelled strand by adding 60
ml of 50 mM NaOH to each well and incubate for 3 min at
room temperature.
10. Transfer the eluted DNA to scintillation vials into 3 ml of
scintillation cocktail and measure the radioactivity in a
beta counter, with 1 min counting time per sample.
11. Data analysis:
After exporting the data, analyse the counts-per-minute
(CPM) values for each nucleotide independently. Subtract
the blank value from all samples measuring that nucleo-
tide. Next, generate a linear standard curve from the origin
(Fig. 1B), and use the regression slope to calculate the
Figure 2: (A) Illustrative dNTP concentration profiles from an array of cell lines. Error bars represent the standard deviation of two technical replicates.
(B) Concentration values obtained from the measurement of the same sample on different days (SH-SY5Y 1 vs. 2 and HEK293 1 vs. 2) and from independently cultured
samples of the same cell line (SH-SY5Y 1–2 vs. 3 and Myotubes 1 vs. 2), as well as the values for the cell lines plotted above, 6 standard deviation between two technical
replicates. The SEM is also calculated to assess the variability between the replicates. (C–D) Comparison between the dNTP concentration values of identical isolates of
mouse bone marrow cells (n¼6) measured with the traditional filter-based protocol or with the present solid-phase methodology in technical duplicates. Data in (C) is
represented as means of the values of each bone marrow isolate from a separate mouse. Each data point in (D) represents the value for a single mouse individual
obtained from technical duplicates. Error bars represent standard deviation. iPSC, induced pluripotent stem cells; NSP, neurospheres.
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concentration of the measured replicates based on their
CPM values. Values outside the range of standards should
be omitted and re-measured at a different dilution. Then
use the cell number and dilution factors utilized to calcu-
late the amount of dNTP per number of cells (Fig. 1C).
Results
The assay was performed on an array of different cell lines. The
standard curves show consistently strong linearity within the
measurement range, with R2 values for the regression 0.99
(Fig. 1B). Each line or cell type presented a particular dNTP pool
profile (Fig. 2A). The measurements show good reproducibility
with same samples measured on different days (SH-SY5Y 1 vs.
2 and HEK293 1 vs. 2), as well as with independently cultured
(and differentiated in case of myotubes) samples from a same
cell line (SH-SY5Y 1–2 vs. 3 and myotubes 1–2) (Fig. 2B).
Finally, in order to compare the performance of the method-
ology with the traditional one from in vivo samples, instead of
cell lines, we measured identical aliquots of freshly isolated
mouse bone marrow extracts with a modified version of the
protocol in [23] for whole cell lysates, and with the present
method. The resulting values (Fig. 2C–D) show very similar
dNTP concentration landscapes, with a tendency of increased
absolute value, particularly strong, concerning the measure-
ment of dTTP.
Discussion
We report here a development to the current state-of-the-art
methodology for quantitative measurement of the four canoni-
cal dNTPs from biological samples. The method allows the per-
formance of the measurement in a solid-phase multiwell
setting, and the microtitre-plate format allows automation of
the pipetting and washing steps, as well as circumventing time-
consuming primer preparation and filter-based steps from the
previous methods [23]. Furthermore, it allows utilization of opti-
mized reaction buffers and template sequences. All these fea-
tures dramatically reduce the required analysis steps, time and
manual work required, diminishing the potential sources of er-
ror. Importantly, it also increases method safety, reducing direct
contact with hazardous compounds.
The main observable difference in the results obtained with
the new methodology compared to the conventional filter-
based method is the tendency to higher absolute concentra-
tions, particularly for dTTP. The consistent standard curve
linearity, the nature of dTTP as the most concentrated canoni-
cal dNTP in the cell and the reduction of steps that could poten-
tially lead to loss of sample in the method, as well as the
unlikely possibility of consistent contamination or signal acqui-
sition specific for dTTP, prompts us to propose that the higher
values may be a true improvement in the sensitivity of the
method.
The current shortcoming of the methodology is the increase
of the reaction volume due to the nature of the well, leading to a
larger requirement of sample and reagents. Moreover, the nor-
malization strategy is a challenge in the field [1], due to the in-
accuracy of cell counting and difficulties comparing
results from different publications. The most widely used nor-
malization method is cell number, although other strategies are
possible, such as utilizing the absorbance of an alkaline lysate,
proportional to cell mass [26]. The consistency of the results
obtained by cell number normalization lead us to utilize it due
to its simplicity, but a more sensitive approach should be
considered for more challenging biological samples, such as
protein or DNA content measurement, or evaluation of cell vol-
ume for molar concentration presentation.
The methanol-based nucleotide isolation is commonly used
for dNTP measurements and hence was chosen for this meth-
odology. However, methanol extracts have been described to
present residual levels of enzymes that could interfere with the
polymerase reaction [27]. The boiling step between precipita-
tions should aid the inactivation of the remaining enzymatic ac-
tivities [28], but in further development of assay sensitivity,
other alternatives excluding this possibility could be
considered, such as perchlorate/trioctylamine extraction/neu-
tralization [21, 29].
Nucleotide metabolism is one of the main targets of chemo-
therapeutic drugs in cancer, despite the fact that current under-
standing on nucleotide metabolism and tissue-specific features
of dNTP regulation is superficial. Furthermore, mitochondrial
dysfunction has turned out to be a common cause of inherited
degenerative conditions, also causing rare and devastating mi-
tochondrial disorders in children, where nucleoside therapies
are emerging as a potential therapeutic option [12]. Our sensi-
tive, quantitative and efficient method should be a highly useful
tool to provide evidence of dNTP metabolism in different biolog-
ical samples, in pathological states and in treatment of cancer
and metabolic diseases.
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